{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:56:25Z","timestamp":1783065385075,"version":"3.54.6"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09563-w","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T07:01:55Z","timestamp":1714028515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-6636","authenticated-orcid":false,"given":"Cansu","family":"Y\u0131ld\u0131r\u0131m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"9563_CR1","doi-asserted-by":"publisher","DOI":"10.1039\/c7nr09436a","author":"IM Yasinska","year":"2018","unstructured":"Yasinska IM, Ceccone G, Ojea-Jimenez I et al (2018) Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates. Nanoscale. https:\/\/doi.org\/10.1039\/c7nr09436a","journal-title":"Nanoscale"},{"key":"9563_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.imlet.2014.03.001","volume":"159","author":"A Poggi","year":"2014","unstructured":"Poggi A, Musso A, Dapino I, Zocchi MR (2014) Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett 159:55\u201372. https:\/\/doi.org\/10.1016\/j.imlet.2014.03.001","journal-title":"Immunol Lett"},{"key":"9563_CR3","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399408000719","volume":"10","author":"R-Y Yang","year":"2008","unstructured":"Yang R-Y, Rabinovich GA, Liu F-T (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17. https:\/\/doi.org\/10.1017\/S1462399408000719","journal-title":"Expert Rev Mol Med"},{"key":"9563_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124347","volume":"10","author":"C Y\u0131ld\u0131r\u0131m","year":"2015","unstructured":"Y\u0131ld\u0131r\u0131m C, Vogel DYS, Hollander MR et al (2015) Galectin-2 induces a proinflammatory, anti-arteriogenic phenotype in monocytes and macrophages. PLoS ONE 10:e0124347. https:\/\/doi.org\/10.1371\/journal.pone.0124347","journal-title":"PLoS ONE"},{"key":"9563_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143629","author":"Z Kocibalova","year":"2021","unstructured":"Kocibalova Z, Guzyova M, Borovska I et al (2021) Development of multidrug resistance in acute myeloid leukemia is associated with alterations of the LPHN1\/GAL-9\/TIM-3 signaling pathway. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13143629","journal-title":"Cancers (Basel)"},{"key":"9563_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver N, Wei AH, Pollyea DA et al (2020) New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J 10:107. https:\/\/doi.org\/10.1038\/s41408-020-00376-1","journal-title":"Blood Cancer J"},{"key":"9563_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","volume":"15","author":"MR O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN et al (2017) Acute myeloid leukemia, version 3.2017, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:926\u2013957. https:\/\/doi.org\/10.6004\/jnccn.2017.0116","journal-title":"J Natl Compr Canc Netw"},{"key":"9563_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/ajh.23404","volume":"88","author":"EH Estey","year":"2013","unstructured":"Estey EH (2013) Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 88:318\u2013327. https:\/\/doi.org\/10.1002\/ajh.23404","journal-title":"Am J Hematol"},{"key":"9563_CR9","first-page":"153","volume-title":"Acute myeloid leukemia stem cell heterogeneity and its clinical relevance","author":"T Karantanos","year":"2019","unstructured":"Karantanos T, Jones RJ (2019) Acute myeloid leukemia stem cell heterogeneity and its clinical relevance. Springer, Cham, pp 153\u2013169"},{"key":"9563_CR10","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.2147\/OTT.S191621","volume":"12","author":"J Zhang","year":"2019","unstructured":"Zhang J, Gu Y, Chen B (2019) Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther 12:1937\u20131945. https:\/\/doi.org\/10.2147\/OTT.S191621","journal-title":"Onco Targets Ther"},{"key":"9563_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1195535","volume":"5","author":"I Gon\u00e7alves Silva","year":"2016","unstructured":"Gon\u00e7alves Silva I, R\u00fcegg L, Gibbs BF et al (2016) The immune receptor Tim-3 acts as a trafficker in a Tim-3\/galectin-9 autocrine loop in human myeloid leukemia cells. Oncoimmunology 5:e1195535. https:\/\/doi.org\/10.1080\/2162402X.2016.1195535","journal-title":"Oncoimmunology"},{"key":"9563_CR12","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.7150\/jca.53686","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Xue S, Hao Q et al (2021) Galectin-9 and PSMB8 overexpression predict unfavorable prognosis in patients with AML. J Cancer 12:4257\u20134263. https:\/\/doi.org\/10.7150\/jca.53686","journal-title":"J Cancer"},{"key":"9563_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, Miyamoto T, Yuda J et al (2015) A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell 17:341\u2013352. https:\/\/doi.org\/10.1016\/j.stem.2015.07.011","journal-title":"Cell Stem Cell"},{"key":"9563_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41423-018-0047-6","volume":"15","author":"IM Yasinska","year":"2018","unstructured":"Yasinska IM, Gon\u00e7alves Silva I, Sakhnevych S et al (2018) Biochemical mechanisms implemented by human acute myeloid leukemia cells to suppress host immune surveillance. Cell Mol Immunol 15:989\u2013991. https:\/\/doi.org\/10.1038\/s41423-018-0047-6","journal-title":"Cell Mol Immunol"},{"key":"9563_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580557","author":"IM Yasinska","year":"2020","unstructured":"Yasinska IM, Meyer NH, Schlichtner S et al (2020) Ligand-receptor interactions of Galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.580557","journal-title":"Front Immunol"},{"key":"9563_CR16","doi-asserted-by":"publisher","first-page":"34529","DOI":"10.1074\/jbc.M113.488478","volume":"288","author":"K M\u00f6ller-Hackbarth","year":"2013","unstructured":"M\u00f6ller-Hackbarth K, Dewitz C, Schweigert O et al (2013) A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3). J Biol Chem 288:34529\u201334544. https:\/\/doi.org\/10.1074\/jbc.M113.488478","journal-title":"J Biol Chem"},{"key":"9563_CR17","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1158\/0008-5472.CAN-11-1487","volume":"71","author":"SF Ngiow","year":"2011","unstructured":"Ngiow SF, Teng MWL, Smyth MJ (2011) Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 71:6567\u20136571. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1487","journal-title":"Cancer Res"},{"key":"9563_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A et al (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245\u20131252. https:\/\/doi.org\/10.1038\/ni1271","journal-title":"Nat Immunol"},{"key":"9563_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/intimm\/dxm044","volume":"19","author":"PR Wilker","year":"2007","unstructured":"Wilker PR, Sedy JR, Grigura V et al (2007) Evidence for carbohydrate recognition and homotypic and heterotypic binding by the TIM family. Int Immunol 19:763\u2013773. https:\/\/doi.org\/10.1093\/intimm\/dxm044","journal-title":"Int Immunol"},{"key":"9563_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","volume":"22","author":"I Gon\u00e7alves Silva","year":"2017","unstructured":"Gon\u00e7alves Silva I, Yasinska IM, Sakhnevych SS et al (2017) The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine 22:44\u201357. https:\/\/doi.org\/10.1016\/j.ebiom.2017.07.018","journal-title":"EBioMedicine"},{"key":"9563_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4149\/gpb_2018008","volume":"37","author":"Z Kocibalova","year":"2018","unstructured":"Kocibalova Z, Guzyova M, Imrichova D et al (2018) Overexpression of the ABCB1 drug transporter in acute myeloid leukemia cells is associated with downregulation of latrophilin-1. Gen Physiol Biophys 37:353\u2013357. https:\/\/doi.org\/10.4149\/gpb_2018008","journal-title":"Gen Physiol Biophys"},{"key":"9563_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","volume":"7","author":"P Dama","year":"2019","unstructured":"Dama P, Tang M, Fulton N et al (2019) Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer 7:175. https:\/\/doi.org\/10.1186\/s40425-019-0611-3","journal-title":"J Immunother Cancer"},{"key":"9563_CR23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3892\/ol.2016.4774","volume":"12","author":"H Horlad","year":"2016","unstructured":"Horlad H, Ohnishi K, Ma C et al (2016) TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia\/lymphoma. Oncol Lett 12:1519\u20131524. https:\/\/doi.org\/10.3892\/ol.2016.4774","journal-title":"Oncol Lett"},{"key":"9563_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/leu.2010.273","volume":"25","author":"J Otten","year":"2011","unstructured":"Otten J, Schmitz L, Vettorazzi E et al (2011) Expression of TGF-\u03b2 receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia. Leukemia 25:375\u2013379. https:\/\/doi.org\/10.1038\/leu.2010.273","journal-title":"Leukemia"},{"key":"9563_CR25","doi-asserted-by":"publisher","first-page":"23478","DOI":"10.18632\/aging.202343","volume":"12","author":"ATH Seln\u00f8","year":"2020","unstructured":"Seln\u00f8 ATH, Schlichtner S, Yasinska IM et al (2020) Transforming growth factor beta type 1 (TGF-\u03b2) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells. Aging 12:23478\u201323496. https:\/\/doi.org\/10.18632\/aging.202343","journal-title":"Aging"},{"key":"9563_CR26","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Munger ME, Veenstra RG et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117:4501\u20134510. https:\/\/doi.org\/10.1182\/blood-2010-10-310425","journal-title":"Blood"},{"key":"9563_CR27","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41419-022-05123-x","volume":"13","author":"M Zhong","year":"2022","unstructured":"Zhong M, Gao R, Zhao R et al (2022) BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. Cell Death Dis 13:671. https:\/\/doi.org\/10.1038\/s41419-022-05123-x","journal-title":"Cell Death Dis"},{"key":"9563_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1164\/rccm.200608-1243OC","volume":"176","author":"S Katoh","year":"2007","unstructured":"Katoh S, Ishii N, Nobumoto A et al (2007) Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 176:27\u201335. https:\/\/doi.org\/10.1164\/rccm.200608-1243OC","journal-title":"Am J Respir Crit Care Med"},{"key":"9563_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.immuni.2014.06.011","volume":"41","author":"C Wu","year":"2014","unstructured":"Wu C, Thalhamer T, Franca RF et al (2014) Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 41:270\u2013282. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.011","journal-title":"Immunity"},{"key":"9563_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.790995","author":"S Schlichtner","year":"2022","unstructured":"Schlichtner S, Yasinska IM, Ruggiero S et al (2022) Expression of the immune checkpoint protein VISTA is differentially regulated by the TGF-\u03b21\u2013Smad3 signaling pathway in rapidly proliferating human cells and T lymphocytes. Front Med (Lausanne). https:\/\/doi.org\/10.3389\/fmed.2022.790995","journal-title":"Front Med (Lausanne)"},{"key":"9563_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-015-0134-4","volume":"8","author":"V Folgiero","year":"2015","unstructured":"Folgiero V, Cifaldi L, Pira GL et al (2015) TIM-3\/Gal-9 interaction induces IFN\u03b3-dependent IDO1 expression in acute myeloid leukemia blast cells. J Hematol Oncol 8:36. https:\/\/doi.org\/10.1186\/s13045-015-0134-4","journal-title":"J Hematol Oncol"},{"key":"9563_CR32","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.18632\/oncotarget.1504","volume":"5","author":"V Folgiero","year":"2014","unstructured":"Folgiero V, Goffredo BM, Filippini P et al (2014) Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 5:2052\u20132064. https:\/\/doi.org\/10.18632\/oncotarget.1504","journal-title":"Oncotarget"},{"key":"9563_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3389\/fimmu.2014.00585","volume":"5","author":"GC Prendergast","year":"2014","unstructured":"Prendergast GC, Metz R, Muller AJ et al (2014) IDO2 in immunomodulation and autoimmune disease. Front Immunol 5:585. https:\/\/doi.org\/10.3389\/fimmu.2014.00585","journal-title":"Front Immunol"},{"key":"9563_CR34","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","volume":"119","author":"MK Gleason","year":"2012","unstructured":"Gleason MK, Lenvik TR, McCullar V et al (2012) Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 119:3064\u20133072. https:\/\/doi.org\/10.1182\/blood-2011-06-360321","journal-title":"Blood"},{"key":"9563_CR35","doi-asserted-by":"publisher","DOI":"10.31744\/einstein_journal\/2023AO0171","author":"SM Gama","year":"2023","unstructured":"Gama SM, Varela VA, Ribeiro NM et al (2023) AKT inhibition interferes with the expression of immune checkpoint proteins and increases NK-induced killing of HL60-AML cells. Einstein (Sao Paulo). https:\/\/doi.org\/10.31744\/einstein_journal\/2023AO0171","journal-title":"Einstein (Sao Paulo)"},{"key":"9563_CR36","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li C-F et al (2021) Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 12:832. https:\/\/doi.org\/10.1038\/s41467-021-21099-2","journal-title":"Nat Commun"},{"key":"9563_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1600-065X.2009.00772.x","volume":"229","author":"R Rodriguez-Manzanet","year":"2009","unstructured":"Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT (2009) The costimulatory role of TIM molecules. Immunol Rev 229:259\u2013270. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00772.x","journal-title":"Immunol Rev"},{"key":"9563_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1749-6632.2012.06550.x","volume":"1266","author":"Y Kikushige","year":"2012","unstructured":"Kikushige Y, Akashi K (2012) TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann N Y Acad Sci 1266:118\u2013123. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06550.x","journal-title":"Ann N Y Acad Sci"},{"key":"9563_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.biocel.2014.11.017","volume":"59","author":"A Prokhorov","year":"2015","unstructured":"Prokhorov A, Gibbs BF, Bardelli M et al (2015) The immune receptor Tim-3 mediates activation of PI3 kinase\/mTOR and HIF-1 pathways in human myeloid leukaemia cells. Int J Biochem Cell Biol 59:11\u201320. https:\/\/doi.org\/10.1016\/j.biocel.2014.11.017","journal-title":"Int J Biochem Cell Biol"},{"key":"9563_CR40","doi-asserted-by":"publisher","first-page":"33823","DOI":"10.18632\/oncotarget.5257","volume":"6","author":"I Gon\u00e7alves Silva","year":"2015","unstructured":"Gon\u00e7alves Silva I, Gibbs BF, Bardelli M et al (2015) Differential expression and biochemical activity of the immune receptor Tim-3 in healthy and malignant human myeloid cells. Oncotarget 6:33823\u201333. https:\/\/doi.org\/10.18632\/oncotarget.5257","journal-title":"Oncotarget"},{"key":"9563_CR41","doi-asserted-by":"publisher","first-page":"7660","DOI":"10.4049\/jimmunol.181.11.7660","volume":"181","author":"K Nagahara","year":"2008","unstructured":"Nagahara K, Arikawa T, Oomizu S et al (2008) Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181:7660\u20137669. https:\/\/doi.org\/10.4049\/jimmunol.181.11.7660","journal-title":"J Immunol"},{"key":"9563_CR42","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/bloodadvances.2022008405","volume":"7","author":"T Sakoda","year":"2023","unstructured":"Sakoda T, Kikushige Y, Miyamoto T et al (2023) TIM-3 signaling hijacks the canonical Wnt\/\u03b2-catenin pathway to maintain cancer stemness in acute myeloid leukemia. Blood Adv 7:2053\u20132065. https:\/\/doi.org\/10.1182\/bloodadvances.2022008405","journal-title":"Blood Adv"},{"key":"9563_CR43","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, Krivtsov AV, Sinha AU et al (2010) The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327:1650\u20131653. https:\/\/doi.org\/10.1126\/science.1186624","journal-title":"Science"},{"key":"9563_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2012.12.012","volume":"152","author":"S Schwitalla","year":"2013","unstructured":"Schwitalla S, Fingerle AA, Cammareri P et al (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152:25\u201338. https:\/\/doi.org\/10.1016\/j.cell.2012.12.012","journal-title":"Cell"},{"key":"9563_CR45","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, Shima T, Takayanagi S et al (2010) TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7:708\u2013717. https:\/\/doi.org\/10.1016\/j.stem.2010.11.014","journal-title":"Cell Stem Cell"},{"key":"9563_CR46","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"C-H Pui","year":"2006","unstructured":"Pui C-H, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166\u2013178. https:\/\/doi.org\/10.1056\/NEJMra052603","journal-title":"N Engl J Med"},{"key":"9563_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","volume":"214","author":"C Haas","year":"2009","unstructured":"Haas C, Krinner E, Brischwein K et al (2009) Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214:441\u2013453. https:\/\/doi.org\/10.1016\/j.imbio.2008.11.014","journal-title":"Immunobiology"},{"key":"9563_CR48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"9563_CR49","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht J, Kayser S, Gorodezki D et al (2016) T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80\/CD86 on leukemic blasts. Oncotarget 7:76902\u201376919. https:\/\/doi.org\/10.18632\/oncotarget.12357","journal-title":"Oncotarget"},{"key":"9563_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","volume":"132","author":"J Webster","year":"2018","unstructured":"Webster J, Luskin MR, Prince GT et al (2018) Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): preliminary results of a phase I study. Blood 132:557. https:\/\/doi.org\/10.1182\/blood-2018-99-111845","journal-title":"Blood"},{"key":"9563_CR51","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s12185-020-03047-w","volume":"113","author":"T Kobayashi","year":"2021","unstructured":"Kobayashi T, Ubukawa K, Fujishima M, Takahashi N (2021) Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis. Int J Hematol 113:600\u2013605. https:\/\/doi.org\/10.1007\/s12185-020-03047-w","journal-title":"Int J Hematol"},{"key":"9563_CR52","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41467-022-28839-y","volume":"13","author":"M Lee","year":"2022","unstructured":"Lee M, Hamilton JAG, Talekar GR et al (2022) Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia. Nat Commun 13:1157. https:\/\/doi.org\/10.1038\/s41467-022-28839-y","journal-title":"Nat Commun"},{"key":"9563_CR53","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.critrevonc.2007.04.008","volume":"64","author":"P Ghia","year":"2007","unstructured":"Ghia P, Ferreri AJM, Caligaris-Cappio F (2007) Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 64:234\u2013246. https:\/\/doi.org\/10.1016\/j.critrevonc.2007.04.008","journal-title":"Crit Rev Oncol Hematol"},{"key":"9563_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","volume":"9","author":"S Zhang","year":"2014","unstructured":"Zhang S, Kipps TJ (2014) The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 9:103\u2013118. https:\/\/doi.org\/10.1146\/annurev-pathol-020712-163955","journal-title":"Annu Rev Pathol"},{"key":"9563_CR55","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.22034\/APJCP.2017.18.8.2269","volume":"18","author":"S Taghiloo","year":"2017","unstructured":"Taghiloo S, Allahmoradi E, Ebadi R et al (2017) Upregulation of Galectin-9 and PD-L1 immune checkpoints molecules in patients with chronic lymphocytic leukemia. Asian Pac J Cancer Prev 18:2269\u20132274. https:\/\/doi.org\/10.22034\/APJCP.2017.18.8.2269","journal-title":"Asian Pac J Cancer Prev"},{"key":"9563_CR56","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3892\/ol.2018.9656","volume":"17","author":"K Wdowiak","year":"2019","unstructured":"Wdowiak K, Gallego-Colon E, Francuz T et al (2019) Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. Oncol Lett 17:1019\u20131029. https:\/\/doi.org\/10.3892\/ol.2018.9656","journal-title":"Oncol Lett"},{"key":"9563_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.853","author":"X Alimu","year":"2023","unstructured":"Alimu X, Zhang J, Pang N et al (2023) Galectin-9 and myeloid-derived suppressor cell as prognostic indicators for chronic lymphocytic leukemia. Immun Inflamm Dis. https:\/\/doi.org\/10.1002\/iid3.853","journal-title":"Immun Inflamm Dis"},{"key":"9563_CR58","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","volume":"121","author":"JC Riches","year":"2013","unstructured":"Riches JC, Davies JK, McClanahan F et al (2013) T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121:1612\u20131621. https:\/\/doi.org\/10.1182\/blood-2012-09-457531","journal-title":"Blood"},{"key":"9563_CR59","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/ejh.12880","volume":"98","author":"S Taghiloo","year":"2017","unstructured":"Taghiloo S, Allahmoradi E, Tehrani M et al (2017) Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemia. Eur J Haematol 98:622\u2013631. https:\/\/doi.org\/10.1111\/ejh.12880","journal-title":"Eur J Haematol"},{"key":"9563_CR60","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100013R","volume":"35","author":"N Pang","year":"2021","unstructured":"Pang N, Alimu X, Chen R et al (2021) Activated Galectin-9\/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia. FASEB J 35:e21556. https:\/\/doi.org\/10.1096\/fj.202100013R","journal-title":"FASEB J"},{"key":"9563_CR61","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.3109\/10428194.2014.986479","volume":"56","author":"DP Lad","year":"2015","unstructured":"Lad DP, Varma S, Varma N et al (2015) Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk Lymphoma 56:2424\u20132428. https:\/\/doi.org\/10.3109\/10428194.2014.986479","journal-title":"Leuk Lymphoma"},{"key":"9563_CR62","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","volume":"106","author":"M Beyer","year":"2005","unstructured":"Beyer M, Kochanek M, Darabi K et al (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106:2018\u20132025. https:\/\/doi.org\/10.1182\/blood-2005-02-0642","journal-title":"Blood"},{"key":"9563_CR63","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2217\/fon.14.298","volume":"11","author":"M Yousefi","year":"2015","unstructured":"Yousefi M, Movassaghpour AA, Shamsasenjan K et al (2015) The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. Future Oncol 11:1567\u20131582. https:\/\/doi.org\/10.2217\/fon.14.298","journal-title":"Future Oncol"},{"key":"9563_CR64","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","volume":"124","author":"R Jitschin","year":"2014","unstructured":"Jitschin R, Braun M, B\u00fcttner M et al (2014) CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 124:750\u2013760. https:\/\/doi.org\/10.1182\/blood-2013-12-546416","journal-title":"Blood"},{"key":"9563_CR65","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"W-HS Lee","year":"2021","unstructured":"Lee W-HS, Ye Z, Cheung AMS et al (2021) Effective killing of acute myeloid leukemia by TIM-3 targeted chimeric antigen receptor T cells. Mol Cancer Ther 20:1702\u20131712. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0155","journal-title":"Mol Cancer Ther"},{"key":"9563_CR66","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.ymthe.2017.06.023","volume":"25","author":"T Gefen","year":"2017","unstructured":"Gefen T, Castro I, Muharemagic D et al (2017) A TIM-3 oligonucleotide aptamer enhances T cell functions and potentiates tumor immunity in mice. Mol Ther 25:2280\u20132288. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.023","journal-title":"Mol Ther"},{"key":"9563_CR67","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-020-04167-0","volume":"86","author":"T Zhong","year":"2020","unstructured":"Zhong T, Zhao C, Wang S et al (2020) The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo. Cancer Chemother Pharmacol 86:783\u2013792. https:\/\/doi.org\/10.1007\/s00280-020-04167-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"9563_CR68","doi-asserted-by":"publisher","first-page":"14757","DOI":"10.1021\/acs.jmedchem.1c01336","volume":"64","author":"TA Rietz","year":"2021","unstructured":"Rietz TA, Teuscher KB, Mills JJ et al (2021) Fragment-based discovery of small molecules bound to T-Cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3). J Med Chem 64:14757\u201314772. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01336","journal-title":"J Med Chem"},{"key":"9563_CR69","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/srep01326","volume":"3","author":"CP Garc\u00eda","year":"2013","unstructured":"Garc\u00eda CP, Sumbayev V, Gilliland D et al (2013) Microscopic analysis of the interaction of gold nanoparticles with cells of the innate immune system. Sci Rep 3:1326. https:\/\/doi.org\/10.1038\/srep01326","journal-title":"Sci Rep"},{"key":"9563_CR70","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/smll.201201528","volume":"9","author":"VV Sumbayev","year":"2013","unstructured":"Sumbayev VV, Yasinska IM, Garcia CP et al (2013) Gold nanoparticles downregulate interleukin-1\u03b2-induced pro-inflammatory responses. Small 9:472\u2013477. https:\/\/doi.org\/10.1002\/smll.201201528","journal-title":"Small"},{"key":"9563_CR71","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/blood-2021-145626","volume":"138","author":"AM Zeidan","year":"2021","unstructured":"Zeidan AM, Al-Kali A, Borate U et al (2021) Sabatolimab (MBG453) combination treatment regimens for patients (Pts) with higher-risk myelodysplastic syndromes (HR-MDS): the MDS studies in the stimulus immuno-myeloid clinical trial program. Blood 138:4669\u20134669. https:\/\/doi.org\/10.1182\/blood-2021-145626","journal-title":"Blood"},{"key":"9563_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-136855","volume":"136","author":"AM Brunner","year":"2020","unstructured":"Brunner AM, Esteve J, Porkka K et al (2020) Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): updated results from a phase 1b study. Blood 136:1\u20132. https:\/\/doi.org\/10.1182\/blood-2020-136855","journal-title":"Blood"},{"key":"9563_CR73","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1182\/blood-2019-128178","volume":"134","author":"U Borate","year":"2019","unstructured":"Borate U, Esteve J, Porkka K et al (2019) Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Blood 134:570\u2013570. https:\/\/doi.org\/10.1182\/blood-2019-128178","journal-title":"Blood"},{"key":"9563_CR74","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano G, Gelderblom H, Mach N et al (2021) Phase I\/Ib clinical trial of sabatolimab, an anti\u2013TIM-3 antibody, alone and in combination with spartalizumab, an anti\u2013PD-1 antibody, in advanced solid tumors. Clin Cancer Res 27:3620\u20133629. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4746","journal-title":"Clin Cancer Res"},{"key":"9563_CR75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12026-020-09146-4","volume":"68","author":"H Rezazadeh","year":"2020","unstructured":"Rezazadeh H, Astaneh M, Tehrani M et al (2020) Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8+ T cells in early clinical stages of chronic lymphocytic leukemia. Immunol Res 68:269\u2013279. https:\/\/doi.org\/10.1007\/s12026-020-09146-4","journal-title":"Immunol Res"},{"key":"9563_CR76","doi-asserted-by":"publisher","first-page":"287","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-4.18975","volume":"44","author":"S Jafarkhani","year":"2022","unstructured":"Jafarkhani S, Hossein-Nataj H, Eslami-Jouybari M et al (2022) PD-1 and TIM-3 blocking cannot enhance apoptosis of chronic lymphocytic leukemia cells induced by peripheral blood CD8+ T cells. Exp Oncol 44:287\u2013294. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-44-no-4.18975","journal-title":"Exp Oncol"},{"key":"9563_CR77","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3109\/10428194.2014.953150","volume":"56","author":"K Fukuno","year":"2015","unstructured":"Fukuno K, Hara T, Tsurumi H et al (2015) Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. Leuk Lymphoma 56:1398\u20131405. https:\/\/doi.org\/10.3109\/10428194.2014.953150","journal-title":"Leuk Lymphoma"},{"key":"9563_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651687","author":"G Wells","year":"2021","unstructured":"Wells G, Kennedy PT, Dahal LN (2021) Investigating the role of indoleamine 2,3-dioxygenase in acute myeloid leukemia: a systematic review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.651687","journal-title":"Front Immunol"},{"key":"9563_CR79","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/10428194.2015.1041388","volume":"57","author":"R Mabuchi","year":"2016","unstructured":"Mabuchi R, Hara T, Matsumoto T et al (2016) High serum concentration of l-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. Leuk Lymphoma 57:92\u201398. https:\/\/doi.org\/10.3109\/10428194.2015.1041388","journal-title":"Leuk Lymphoma"},{"key":"9563_CR80","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1002\/cam4.5549","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, Ou J, Liu N et al (2023) Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia. Cancer Med 12:8956\u20138969. https:\/\/doi.org\/10.1002\/cam4.5549","journal-title":"Cancer Med"},{"key":"9563_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265299","author":"H Cao","year":"2023","unstructured":"Cao H, Wu T, Zhou X et al (2023) Progress of research on PD-1\/PD-L1 in leukemia. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1265299","journal-title":"Front Immunol"},{"key":"9563_CR82","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s40001-023-01352-8","volume":"28","author":"Y Ruan","year":"2023","unstructured":"Ruan Y, Wang J, Zhang Q et al (2023) Clinical implications of aberrant PD-1 expression for acute leukemia prognosis. Eur J Med Res 28:383. https:\/\/doi.org\/10.1186\/s40001-023-01352-8","journal-title":"Eur J Med Res"},{"key":"9563_CR83","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2278229","author":"S Huang","year":"2023","unstructured":"Huang S, Zhao Y, Lai W et al (2023) (2023) Higher PD-1\/Tim-3 expression on IFN-\u03b3+ T cells is associated with poor prognosis in patients with acute myeloid leukemia. Cancer Biol Ther. https:\/\/doi.org\/10.1080\/15384047.2278229","journal-title":"Cancer Biol Ther"},{"key":"9563_CR84","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0443","author":"J Zeng","year":"2023","unstructured":"Zeng J, Yao J, Zhou Y et al (2023) Expression of interferon regulatory factor family and its prognostic value in acute myeloid leukemia. Future Oncol. https:\/\/doi.org\/10.2217\/fon-2023-0443","journal-title":"Future Oncol"},{"key":"9563_CR85","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.leukres.2010.10.020","volume":"35","author":"G Deeb","year":"2011","unstructured":"Deeb G, Vaughan MM, McInnis I et al (2011) Hypoxia-inducible factor-1\u03b1 protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 35:579\u2013584. https:\/\/doi.org\/10.1016\/j.leukres.2010.10.020","journal-title":"Leuk Res"},{"key":"9563_CR86","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/sj.leu.2404239","volume":"20","author":"L Ysebaert","year":"2006","unstructured":"Ysebaert L, Chicanne G, Demur C et al (2006) Expression of \u03b2-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 20:1211\u20131216. https:\/\/doi.org\/10.1038\/sj.leu.2404239","journal-title":"Leukemia"},{"key":"9563_CR87","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12288-022-01569-3","volume":"39","author":"N Osman","year":"2023","unstructured":"Osman N, ELzayat R, ELtounsi I (2023) Higher mTOR expression: a marker of poor outcome in patients with de Novo AML. Indian J Hematol Blood Transf 39:325\u2013329. https:\/\/doi.org\/10.1007\/s12288-022-01569-3","journal-title":"Indian J Hematol Blood Transf"},{"key":"9563_CR88","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1038\/s41598-024-57578-x","volume":"14","author":"E Corre","year":"2024","unstructured":"Corre E, Soum C, Pfeifer R et al (2024) Differential prognostic values of the three AKT isoforms in acute myeloid leukemia. Sci Rep 14:7070. https:\/\/doi.org\/10.1038\/s41598-024-57578-x","journal-title":"Sci Rep"},{"key":"9563_CR89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-023-01410-y","volume":"16","author":"J Mo","year":"2023","unstructured":"Mo J, Deng L, Peng K et al (2023) Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia. J Hematol Oncol 16:15. https:\/\/doi.org\/10.1186\/s13045-023-01410-y","journal-title":"J Hematol Oncol"},{"key":"9563_CR90","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00277-011-1161-z","volume":"90","author":"MK Hertweck","year":"2011","unstructured":"Hertweck MK, Erdfelder F, Kreuzer K-A (2011) CD44 in hematological neoplasias. Ann Hematol 90:493\u2013508. https:\/\/doi.org\/10.1007\/s00277-011-1161-z","journal-title":"Ann Hematol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09563-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09563-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09563-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T20:41:59Z","timestamp":1738701719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09563-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9563"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09563-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author has no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"571"}}